Dr. Waldman is the Chief Executive Officer of Veradermics. Under his stewardship, he has positioned Veradermics for rapid growth by implementing a differentiated strategy centered on advancing first-in-class therapeutics for under-innovated markets in aesthetics and dermatology. He has also successfully led the company through significant equity financings, and has advanced Veradermics lead asset, VDPHL01, a potential non-hormonal oral treatment for pattern hair loss, into Phase 3 trials. The company recently went public, delivering one of the most successful biotech IPO performances of the year, and now trades on the New York Stock Exchange under the ticker MANE. Dr. Waldman is a board-certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a prolific researcher authoring more than 100 publications including a textbook titled, “Dermatology for the Primary Care Provider.” He has been the recipient of numerous accolades including the American Academy of Dermatology’s “Excellence in Patient Care” award. He earned his BA and his MD degrees from the University of Missouri-Kansas City 6 Year BA/MD Program and completed his dermatology residency with a “Distinction in Clinical Trials” at the University of Connecticut.